HomeAI · summaries
Storia in 5 fonti
Tariffs alone will not produce sustainable generic medicine in US: IPA
The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair pricing and supply chain stability. India supplies nearly fifty percent of generic medicines to the United States. Tariffs alone will not produce sustainable generic medicine onshoring. Reforms should address upstream buying groups and delayed generic competition.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm
Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…
- ·
Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?
The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching…
- ·
Trump’s 100% generic drug duty threatens US low-cost supply
President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…
- ·
200% Trump tariff shock? India’s cheap pills may still beat US rivals
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…
- ·
Indian pharma firms may yet survive Trump's 200% tariff bombshell
Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…
- ·
timesofindia.indiatimes.com
Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.
- ·
thehindubusinessline.com
US proposal to impose steep tariffs on generic medicines could significantly impact India: GTRI
US tariffs on generic medicines may drastically affect India's pharmaceutical exports, particularly in higher-value formulations, warns GTRI.
- ·
asia.nikkei.com
Trump's generic drugs tariff threatens Indian pharma's top market
100% levy from 2028 could accelerate push into higher value medicines
- ·
Tariffs alone will not produce sustainable generic medicine in US: IPA
The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair pricing and supply chain stability.…
- ·
zerohedge.com
UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners
"For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA..."
- ·
US tariffs could raise drug prices, squeeze Indian generics
NEW DELHI: India's $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face…
- ·
Trump's 200% tariff plan may be a bitter pill for US consumers; Dr Reddy's warns of costlier medicines
The US is putting generic medicines on the tariff map, with duties set to rise to as much as 200% in the coming years to boost local manufacturing. But will the cure soothe the…